IP Library Granted Patent US 7,727,531
Granted Patent B2
US 7,727,531 · App. 12/257,420 · Granted Jun 1, 2010

Antibodies for preventing and treating attaching and effacing

Assignee: Valorisation-Recherche, Societe En commandite
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,727,531
App. No.
12/257,420
Granted
Jun 1, 2010
Kind
B2
Abstract

The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.

Claims (7)

1. A method for preventing the development of attaching and effacing (A/E) intestinal lesions associated with an attaching and effacing Escherichia coli (AEEC) in a mammal, said method comprising: oral administration to the mammal of an IgY antibody immunologically specific to an AEEC virulence-associated protein, wherein the AEEC virulence-associated protein is porcine attaching-effacing associated protein Paa.

2. The method of claim 1 , wherein the IgY antibody is isolated and purified.

3. The method of claim 1 , wherein the IgY antibody is combined with a biologically acceptable vehicle or carrier.

4. The method of claim 1 , wherein the IgY antibody is comprised in an egg.

5. The method of claim 1 , wherein the IgY antibody is comprised in an isolated yolk of an egg.

6. The method of claim 4 , wherein the egg is lyophilized and is administered in a powdered form.

7. The method of claim 5 , wherein the isolated yolk is lyophilized and is administered in a powdered form.

Assignments (3)
MERGER Recorded Aug 28, 2020
From: PREVTEC MICROBIA INC
To: ELANCO CANADA LIMITED
Reel/Frame 053633/0994 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2020
From: PREVTEC MICROBIA INC.
To: ELANCO CANADA LIMITED
Reel/Frame 053294/0879 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2015
From: VALORISATION-RECHERCHE, LIMITED PARTNERSHIP
To: PREVTEC MICROBIA INC.
Reel/Frame 035411/0477 →
Priority Claims (1)
CA 2339436 · Mar 15, 2001 · national
Continuity (2)
Division 1047191400
Related Publication 20090092621A1 · Apr 9, 2009